

ZKB Tracker Certificate Dynamic on a BLKB iQ Responsible Regio Basel Basket

24.09.2019 - Open End | Swiss Security Code 42 980 817

Summary

This Summary is to be understood as an introduction to the present Final Terms. Any investment decision in relation to the products must be based on the information contained in the Base Prospectus and in these Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these Final Terms and in the Base Prospectus.

The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the Final Terms and the Base Prospectus.

Information on the securities
Type of product: ZKB Tracker Certificate Dynamic SSPA Category: Tracker Certificate (1300, acc. to the Swiss Derivative Map) ISIN: CH0429808170 Symbol: REGIOZ Issuer: Zürcher Kantonalbank Underlying: a BLKB iQ Responsible Regio Basel Basket Initial Fixing Date: 19 September 2019 Settlement Date: 24 September 2019 Final Fixing Date: --- (Open End) Redemption Date: --- (Open End) Type of settlement: cash
Information concerning the offer and admission to trading
Place of the offer: Switzerland Notional Amount/Denomination/Trading Units: CHF 32'961'200.00/CHF 1'648.06/1 Structured Product or multiples thereof Issue price: CHF 1'648.06 Selling restrictions: EEA, U.S.A./U.S. persons, United Kingdom, Guernsey Information on listing: Application to list on the SIX Swiss Exchange will be filed, the first provisory trading day will be 24 September 2019

New Issue

1. Product Description

Product Category/Name

Participation Product/Tracker Certificate (1300, according to the "Swiss Derivative Map" provided by the Swiss Structured Products Association)

CISA Notification

This is a Structured Product. It does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.

Investment Profile

The composition of the Underlying of this Structured Product is managed **dynamically** and **discretionary** over the course of its term.

The BLKB iQ Responsible Regio Basel Basket contains companies from the Basel region. The Basellandschaftliche Kantonalbank verifies whether there are companies in the universe that are affected by the BLKB sustainability exclusion criterias. These companies are excluded from the universe. The 18 largest companies (free-float-adjusted market capitalisation) can be selected for the basket considering market liquidity. An underweight or overweight is based on the ESG scoring.

Further information about the investment strategy – if available – can be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zürich, department VRIE or by way of e-Mail address documentation@zkb.ch.

Title Universe	The Title Universe consists of the basic universe of the SPI Index and must meet the following criteria: The head office must be within postal code 4000 - 4499, there must be no second head office outside postal code 4000 - 4499, no real estate company (Art. 77) and no investment company (Art. 65). The own listed securities of the Basellandschaftliche Kantonalbank (e.g. CH0001473559) are not part of the universe. The Basellandschaftliche Kantonalbank verifies whether there are companies among the titles of the universe that are affected by the BLKB sustainability exclusion criteria. These companies are excluded from the universe. The BLKB exclusion criteria with regards to sustainability criteria include, for example, climate change (promotion of fossil fuels, operation of fossil power plants, manufacture of aircraft/airlines, etc.), damage to health (tobacco, gambling, nuclear energy, etc.), ethics (weapons, adult entertainment, etc.) and reduction of biodiversity (genetically modified seeds, etc.). The BLKB sustainability criterias are continuously reviewed and adjusted if necessary. The Underlying constituents are listed at a recognized exchange (World Federation of Exchanges or FESE (Federation of European Securities Exchanges)). The current composition of the Underlying can be found under www.zkb.ch/strukturierteprodukte .
Rebalancing	The Investment Manager rebalances the portfolio composition rule-based, based on the ESG scoring, generally four times a year, in March, June, September and December. Extraordinary adjustments may be made at the discretion of the Investment Manager, also outside the defined dates. The Investment Manager considers only Underlying Components which provide sufficient liquidity and tradability. The Rebalancing is based on net prices of the Underlying Components (average of the net prices of the Underlying Components converted into the basket currency by the Issuer). The fixing period of the rebalancing may be extended by the Issuer in its sole discretion if it considers this necessary due to current market conditions (such as liquidity). The current basket composition is listed in the Annex to this termsheet.
Issuer	Zürcher Kantonalbank, Zurich
Rating of the Issuer	Standard & Poor's AAA, Moody's Aaa, Fitch AAA
Lead Manager, Paying Agent, Exercise Agent and Calculation Agent	Zürcher Kantonalbank, Zurich
Investment Manager	Basellandschaftliche Kantonalbank, Liestal
Symbol/ Swiss Security Code/ISIN	REGIOZ/ 42 980 817/CH0429808170
Notional Amount/Denomination/ Trading Units	CHF 32'961'200.00/CHF 1'648.06/1 Structured Product or multiples thereof
Number of Structured Products	Up to 20'000, with the right to increase
Issue Price	CHF 1'648.06 / 100.00% of Basket Value on the Initial Fixing Date
Currency	CHF

Underlying per Initial Fixing Date	Component	ISIN / Bloomberg	Related Exchange	*Currency / Initial Fixing Value	Weight in %	No. of Shares/ Amount
	Roche Holding Ltd	CH0012032048 /ROG SE	SIX Swiss Exchange	CHF 283.0000	16.06	0.935261
	Novartis AG	CH0012005267 /NOVN SE	SIX Swiss Exchange	CHF 85.8800	13.92	2.671288
	Lonza Group AG	CH0013841017 /LONN SE	SIX Swiss Exchange	CHF 346.1000	6.38	0.303803
	Valora Holding AG	CH0002088976 /VALN SE	SIX Swiss Exchange	CHF 271.0000	6.38	0.387994
	Bell AG	CH0315966322 /BELL SE	SIX Swiss Exchange	CHF 262.5000	5.87	0.368538
	Clariant AG	CH0012142631 /CLN SE	SIX Swiss Exchange	CHF 20.0500	5.87	4.825000
	Dufry AG	CH0023405456 /DUFN SE	SIX Swiss Exchange	CHF 84.1400	5.35	1.047912
	Straumann Holding AG	CH0012280076 /STMN SE	SIX Swiss Exchange	CHF 810.6000	5.35	0.108773
	Basler Kantonalbank	CH0009236461 /BSKP SE	SIX Swiss Exchange	CHF 71.0000	4.64	1.077043
	Idorsia AG	CH0363463438 /IDIA SE	SIX Swiss Exchange	CHF 25.4200	4.64	3.008264
	Bachem Holding AG	CH0012530207 /BANB SE	SIX Swiss Exchange	CHF 145.0000	4.12	0.468277
	Bâloise-Holding AG	CH0012410517 /BALN SE	SIX Swiss Exchange	CHF 174.6000	4.12	0.388890
	Basilea Pharmaceutica AG	CH0011432447 /BSLN SE	SIX Swiss Exchange	CHF 45.2200	4.12	1.501551
	Medartis Holding AG	CH0386200239 /MED SE	SIX Swiss Exchange	CHF 43.8000	3.52	1.324470
	Evolva Holding AG	CH0021218067 /EVE SE	SIX Swiss Exchange	CHF 0.1690	3.22	314.0094 65
	Polyphor AG	CH0106213793 /POLN SE	SIX Swiss Exchange	CHF 6.5100	3.22	8.151705
	Santhera Pharmaceuticals Holding AG	CH0027148649 /SANN SE	SIX Swiss Exchange	CHF 12.0600	3.22	4.400298

* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the Structured Product. This applies particularly, though not exclusively, when exercising rights associated with the Structured Product and/or a Rebalancing.

Basket Value CHF 1'648.06 on Initial Fixing Date

The terms and conditions of the present product have been adjusted due to Corporate Actions, refer to table Corporate Actions.

Ratio 1 ZKB Tracker Certificate Dynamic represents 1 Underlying

Dividend Payments The Investor will receive a payment as compensation for the dividend payment of the Structured Product. The compensation payment takes place annually on 30 June, for the first time retroactively on 30 June 2020, (modified following business day convention). The compensation payment will correspond to 100.00% of the net dividend payment.

Initial Fixing Date 19 September 2019

Settlement Date 24 September 2019

Redemption right of the Issuer The Issuer has the right to redeem the outstanding Structured Products quarterly on the 15th day of March, June, September and December (fixing date; modified following), for the first time on 16 December 2019. On the fixing date, the redemption amount is determined, which is governed by the information under the section Redemption Method. The Issuer may, under its sole authority, extend the Fixing Date if it deems this necessary due to current market conditions such as liquidity. The announcement and thus the declaration of intent to exercise the Redemption right is made with a notice period of 20 banking days via the official publication channel of the SIX Swiss Exchange. No statement of reasons is required. The redemption will be executed with a value date of 5 bank working days after the fixing date (Redemption Date).

Taxes

The Issuer reports the taxable factors (change to previous year's value) divided in the components income and capital gain to the Swiss Federal Tax Administration on 31 October each year. The income part is subject to Swiss income tax for private investors with Swiss tax domicile as per reporting date. The capital gain part is not subject to Swiss income tax. The product is not subject to Swiss withholding tax. The Federal securities transfer stamp tax is not levied on secondary market transactions. This product may be subject to additional withholding taxes or duties, such as related to FATCA, Sect. 871(m) U.S. Tax Code or foreign financial transaction taxes. Any payments due under this product are net of such taxes or duties.

The information above is a summary only of the Issuer's understanding of current law and practice in Switzerland relating to the taxation of Structured Products. The relevant tax law and practice may change. The Issuer does not assume any liability in connection with the above information. The tax information only provides a general overview and can not substitute the personal tax advice to the investor.

Documentation

This document is a non-binding English translation of the Final Terms (Endgültige Bedingungen) published in German and constituting the Final Terms in accordance with article 45 of the Federal Act on Financial Services (FinSA). The English language translation is provided for convenience only.

The binding German version of these Final Terms supplements the Base Prospectus approved by the SIX Swiss Exchange and published in German by the Issuer on 16 November 2020.

These Final Terms constitute a Simplified prospectus pursuant to article 5 para. 2 CISA in the version dated 1 March 2013. Together with the Base Prospectus (and together with any supplements) these Final Terms form the product documentation for this issue.

If this Product was the first time issued under the Base Prospectus of 16 November 2020, these Final Terms must be read in conjunction with the General Terms of the Securities (Allgemeine Bedingungen der Derivate), the Additional Terms and the Information on the Underlyings in the Base Prospectus of 16 November 2020. If this Product has been issued prior to the date of the Base Prospectus of 16 November 2020, these Final Terms shall be read in conjunction with the Base Prospectus of 16 November 2020 and together with the Existing Terms of the Products from the version of the Issuance Programme or Base Prospectus in force at the time of issuance that has been incorporated by reference in this Base Prospectus.

The Base Prospectus of the Issuer dated 16 November 2020 will cease to be valid on 16 November 2021. From and including this date, these Final Terms must be read together with the latest valid version of the Base Prospectus of the Issuer (including the information incorporated by reference into the latest valid version of the Base Prospectus from the Base Prospectus under which the Products the first time were issued), which follows the Base Prospectus of 16 November 2020.

Except as otherwise defined in these Final Terms, the terms used in these Final Terms have the meaning given to them in the Base Prospectus. In case of discrepancies between information or the provisions in these Final Terms and those in the Base Prospectus, the information and provisions in these Final Terms shall prevail. In the event of a listing of the products, the product documentation will be adapted, if and to the extent necessary, in accordance with the requirements of the relevant exchange. The present products will be issued in the form of uncertificated securities (Wertrechte) and registered as book-entry securities (Bucheffekten) with SIX SIS AG. Investors have no right to require the issuance of any certificates or any proof of evidence for the products.

These Final Terms and the Base Prospectus can be ordered free of charge at Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, dept. VRIE or by e-mail at documentation@zkb.ch. They are also available on <https://www.zkb.ch/finanzinformationen>.

Information on the Underlying

Information on the performance of the Underlying/a component of the Underlying is publicly available on www.bloomberg.com. Current annual reports are published on the website of the respective business entity. The transfer of the Underlying/a component of the Underlying is conducted in accordance with their respective statutes.

Notices

Any notice by the Issuer in connection with these Structured Products, in particular any notice in connection with modifications of the terms and conditions will be validly published on the website <https://zkb-finance.mdgms.com/products/stp/index.html> under the relevant Structured Product. The Swiss security code search button will lead you directly to the relevant Structured Product. The notices will be published in accordance with the rules issued by SIX Swiss Exchange for IBL (Internet Based Listing) on the website <https://www.six-exchange-regulation.com/en/home/publications/official-notices.html>

Governing Law/Jurisdiction

Swiss Law/Zurich

2. Profit and Loss Expectations after Year 1

Profit and Loss Expectations after Year 1

ZKB Tracker Certificate Dynamic

Basket		Redemption	
Value	Percent	ZKB Tracker Certificate Dynamic	Performance %
CHF 1400.85	-15.00%	CHF 1386.84	-15.85%
CHF 1483.25	-10.00%	CHF 1468.42	-10.90%
CHF 1565.66	-5.00%	CHF 1550.00	-5.95%
CHF 1648.06	+0.00%	CHF 1631.58	-1.00%
CHF 1730.46	+5.00%	CHF 1713.16	3.95%
CHF 1812.87	+10.00%	CHF 1794.74	8.90%
CHF 1895.27	+15.00%	CHF 1876.32	13.85%

Source: Zürcher Kantonalbank

The performance of the ZKB Tracker Certificate Dynamic is analog to the performance of the Underlying less any Fees. Rebalancing Fees are not included in the table above.

The figures in the table above are valid after Year 1 only and cannot be considered as a price indication for the present Structured Product during its lifetime. The price quoted in the secondary market can differ substantially from the table above.

3. Material Risks for Investors

Credit Risk Relating to Issuer

Obligations under these Structured Products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the Structured Product does not only depend on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this Structured Product.

Specific Product Risks

Structured Products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks. ZKB Tracker Certificate Dynamic is an investment product whose price fluctuates to the same degree as the Underlying less any Fees. Depending on price trends, the price of a ZKB Tracker Certificate Dynamic could fall below the Issue Price. The risk profile of the ZKB Tracker Certificate Dynamic corresponds to that of the Underlying. The ZKB Tracker Certificate Dynamic is denominated in CHF. If the investor's reference currency differs from the CHF, the investor bears the risk between the CHF and his reference currency.

4. Additional Terms

Modifications

If an extraordinary event as described in Section IV of the Issuance Programme occurs in relation to the Underlying/a component of the Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the Structured Products or to calculate the value of the Structured Products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these Structured Products at its own discretion in such way, that the economic value of the Structured Products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the Structured Products prior to the occurrence of the extraordinary event. Specific modification rules for certain types of Underlyings stated in Section IV of the Issuance Programme shall prevail. If the Issuer determines, for whatever reason, that an adequate modification is not possible, the Issuer has the right to redeem the Structured Products early.

Market Disruptions

Compare specific provisions in the Issuance Programme.

Selling Restrictions

EEA, U.S.A./U.S. persons, GB, Guernsey

Prudential Supervision

As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities dealer within the meaning of the Swiss Federal Act on Securities Exchanges and Securities Trading (BEHG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, <http://www.finma.ch>.

Recording of Telephone Conversations

Investors are reminded that telephone conversations with trading or sales units of Zürcher Kantonalbank are recorded. Investors, engaging in telephone conversations with these units provide their tacit consent to the recording of their conversations.

Further Information

This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the issuance programme. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the Product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.

Material Changes

Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer.

Responsibility for the Final Terms

Zürcher Kantonalbank, Zurich, assumes responsibility for the content of these Final Terms and hereby declares that, to its knowledge, the information contained in these Final Terms is correct and no material circumstances have been omitted.

Zurich, 19 September 2019, last update on 17 December 2020

Underlying on 17 12 2020

Component	ISIN / Bloomberg	Related Exchange	*Currency / Initial Fixing Value	Weight in %	No. of Shares/ Amount
Bachem Holding AG	CH0012530207 /BANB SE	SIX Swiss Exchange	363.0000	4.11	0.198532
Bâloise-Holding AG	CH0012410517 /BALN SE	SIX Swiss Exchange	159.1000	4.26	0.468876
Basilea Pharmaceutica AG	CH0011432447 /BSLN SE	SIX Swiss Exchange	52.5000	4.07	1.359368
Bell AG	CH0315966322 /BELL SE	SIX Swiss Exchange	247.5000	5.76	0.407687
Clariant AG	CH0012142631 /CLN SE	SIX Swiss Exchange	18.3300	5.75	5.499174
Dufry AG	CH0023405456 /DUFN SE	SIX Swiss Exchange	53.0000	4.78	1.580620
Evolva Holding AG	CH0021218067 /EVE SE	SIX Swiss Exchange	0.2030	3.11	268.2937 79
Idorsia AG	CH0363463438 /IDIA SE	SIX Swiss Exchange	25.2600	4.56	3.162287
Basler Kantonalbank	CH0009236461 /BSKP SE	SIX Swiss Exchange	60.0000	4.52	1.320724
Lonza Group AG	CH0013841017 /LONN SE	SIX Swiss Exchange	551.4000	6.32	0.200967
Medartis Holding AG	CH0386200239 /MED SE	SIX Swiss Exchange	45.3500	3.50	1.352060
Novartis AG	CH0012005267 /NOVN SE	SIX Swiss Exchange	81.7000	15.87	3.404577
Polyphor AG	CH0106213793 /POLN SE	SIX Swiss Exchange	8.3400	3.11	6.537471
Roche Holding Ltd	CH0012032048 /ROG SE	SIX Swiss Exchange	309.1000	15.77	0.894296
Santhera Pharmaceuticals Holding AG	CH0027148649 /SANN SE	SIX Swiss Exchange	2.7708	3.03	19.15943 5
Straumann Holding AG	CH0012280076 /STMN SE	SIX Swiss Exchange	1025.0000	5.22	0.089183
Valora Holding AG	CH0002088976 /VALN SE	SIX Swiss Exchange	157.0000	6.27	0.700437

* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the Structured Product. This applies particularly, though not exclusively, when exercising rights associated with the Structured Product and/or a Rebalancing.

Corporate Actions

Date	Underlying	Action		
		Rebalancing on 17.12.2019	Amount old	Amount new
17.12.2019	Bachem Holding AG	Rebalancing	0.468277	0.475612
17.12.2019	Bâloise-Holding AG	Rebalancing	0.388890	0.409383
17.12.2019	Basilea Pharmaceutica AG	Rebalancing	1.501551	1.507858
17.12.2019	Basler Kantonalkbank	Rebalancing	1.077043	1.102130
17.12.2019	Bell AG	Rebalancing	0.368538	0.387074
17.12.2019	Clariant AG	Rebalancing	4.825000	4.825512
17.12.2019	Dufry AG	Rebalancing	1.047912	0.969328
17.12.2019	Evolva Holding AG	Rebalancing	314.009465	333.627322
17.12.2019	Idorsia AG	Rebalancing	3.008264	2.785036
17.12.2019	Lonza Group AG	Rebalancing	0.303803	0.324898
17.12.2019	Medartis Holding AG	Rebalancing	1.324470	1.374253
17.12.2019	Novartis AG	Rebalancing	2.671288	2.667732
17.12.2019	Polyphor AG	Rebalancing	8.151705	7.094056
17.12.2019	Roche Holding Ltd	Rebalancing	0.935261	0.922956
17.12.2019	Santhera Pharmaceuticals Holding AG	Rebalancing	4.400298	4.710277
17.12.2019	Straumann Holding AG	Rebalancing	0.108773	0.098748
17.12.2019	Valora Holding AG	Rebalancing	0.387994	0.416994
		Rebalancing on 18.03.2020	Amount old	Amount new
18.03.2020	Bachem Holding AG	Rebalancing	0.475612	0.340357
18.03.2020	Bâloise-Holding AG	Rebalancing	0.409383	0.455111
18.03.2020	Basilea Pharmaceutica AG	Rebalancing	1.507858	1.884886
18.03.2020	Basler Kantonalkbank	Rebalancing	1.102130	1.048165
18.03.2020	Bell AG	Rebalancing	0.387074	0.365029
18.03.2020	Clariant AG	Rebalancing	4.825512	4.959162
18.03.2020	Dufry AG	Rebalancing	0.969328	3.139012
18.03.2020	Evolva Holding AG	Rebalancing	333.627322	247.054150
18.03.2020	Idorsia AG	Rebalancing	2.785036	2.947546
18.03.2020	Lonza Group AG	Rebalancing	0.324898	0.256297
18.03.2020	Medartis Holding AG	Rebalancing	1.374253	1.371873
18.03.2020	Novartis AG	Rebalancing	2.667732	2.648129
18.03.2020	Polyphor AG	Rebalancing	7.094056	7.827325
18.03.2020	Roche Holding Ltd	Rebalancing	0.922956	0.739425
18.03.2020	Santhera Pharmaceuticals Holding AG	Rebalancing	4.710277	6.760237
18.03.2020	Straumann Holding AG	Rebalancing	0.098748	0.116274
18.03.2020	Valora Holding AG	Rebalancing	0.416994	0.559102
		Rebalancing on 17.06.2020	Amount old	Amount new
17.06.2020	Bachem Holding AG	Rebalancing	0.340357	0.297277
17.06.2020	Bâloise-Holding AG	Rebalancing	0.455111	0.482216
17.06.2020	Basilea Pharmaceutica AG	Rebalancing	1.884886	1.568880
17.06.2020	Basler Kantonalkbank	Rebalancing	1.048165	1.168859
17.06.2020	Bell AG	Rebalancing	0.365029	0.435938
17.06.2020	Clariant AG	Rebalancing	4.959162	5.506386
17.06.2020	Dufry AG	Rebalancing	3.139012	2.596679
17.06.2020	Evolva Holding AG	Rebalancing	247.054150	243.095970
17.06.2020	Idorsia AG	Rebalancing	2.947546	2.728317
17.06.2020	Lonza Group AG	Rebalancing	0.256297	0.226530
17.06.2020	Medartis Holding AG	Rebalancing	1.371873	1.411012
17.06.2020	Novartis AG	Rebalancing	2.648129	2.543356
17.06.2020	Polyphor AG	Rebalancing	7.827325	7.765851
17.06.2020	Roche Holding Ltd	Rebalancing	0.739425	0.837020
17.06.2020	Santhera Pharmaceuticals Holding AG	Rebalancing	6.760237	6.568873
17.06.2020	Straumann Holding AG	Rebalancing	0.116274	0.120176
17.06.2020	Valora Holding AG	Rebalancing	0.559102	0.569779
		Rebalancing on 17.09.2020	Amount old	Amount new
17.09.2020	Bachem Holding AG	Rebalancing	0.297277	0.195737
17.09.2020	Bâloise-Holding AG	Rebalancing	0.482216	0.488674
17.09.2020	Basilea Pharmaceutica AG	Rebalancing	1.568880	1.674722
17.09.2020	Basler Kantonalkbank	Rebalancing	1.168859	1.299712
17.09.2020	Bell AG	Rebalancing	0.435938	0.405103
17.09.2020	Clariant AG	Rebalancing	5.506386	5.433461
17.09.2020	Dufry AG	Rebalancing	2.596679	3.130104
17.09.2020	Evolva Holding AG	Rebalancing	243.095970	233.907519
17.09.2020	Idorsia AG	Rebalancing	2.728317	3.143861
17.09.2020	Lonza Group AG	Rebalancing	0.226530	0.202080
17.09.2020	Medartis Holding AG	Rebalancing	1.411012	1.486217
17.09.2020	Novartis AG	Rebalancing	2.543356	2.592433
17.09.2020	Polyphor AG	Rebalancing	7.765851	7.761723

Corporate Actions

Date	Underlying	Action		
17.09.2020	Roche Holding Ltd	Rebalancing	0.837020	0.845281
17.09.2020	Santhera Pharmaceuticals Holding AG	Rebalancing	6.568873	8.644182
17.09.2020	Straumann Holding AG	Rebalancing	0.120176	0.101584
17.09.2020	Valora Holding AG	Rebalancing	0.569779	0.657622
		Rebalancing on 16.12.2020	Amount old	Amount new
16.12.2020	Bachem Holding AG	Rebalancing	0.195737	0.198532
16.12.2020	Bâloise-Holding AG	Rebalancing	0.488674	0.468876
16.12.2020	Basilea Pharmaceutica AG	Rebalancing	1.674722	1.359368
16.12.2020	Basler Kantonalbank	Rebalancing	1.299712	1.320724
16.12.2020	Bell AG	Rebalancing	0.405103	0.407687
16.12.2020	Cash CHF	Buy	-	19.886275
16.12.2020	Clariant AG	Rebalancing	5.433461	5.499174
16.12.2020	Dufry AG	Rebalancing	3.130104	1.580620
16.12.2020	Evolva Holding AG	Rebalancing	233.907519	268.293779
16.12.2020	Idorsia AG	Rebalancing	3.143861	3.162287
16.12.2020	Lonza Group AG	Rebalancing	0.202080	0.200967
16.12.2020	Medartis Holding AG	Rebalancing	1.486217	1.352060
16.12.2020	Novartis AG	Rebalancing	2.592433	3.404577
16.12.2020	Polyphor AG	Rebalancing	7.761723	6.537471
16.12.2020	Roche Holding Ltd	Rebalancing	0.845281	0.894296
16.12.2020	Santhera Pharmaceuticals Holding AG	Rebalancing	8.644182	11.982474
16.12.2020	Straumann Holding AG	Rebalancing	0.101584	0.089183
16.12.2020	Valora Holding AG	Rebalancing	0.657622	0.700437
		Rebalancing on 17.12.2020	Amount old	Amount new
17.12.2020	Cash CHF	Sell	19.886275	-
17.12.2020	Santhera Pharmaceuticals Holding AG	Rebalancing	11.982474	19.159435